North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024
“North American nuclear medicine market is projected to grow at a CAGR of 4.1%.”
The North American nuclear medicine market is projected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. The North American nuclear medicine market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide.
Growth in the market can primarily be attributed to factors such as increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.
“The Technetium-99m segment to hold the largest share of the SPECT radiopharmaceuticals market in 2019”
Based on type, the SPECT Radiopharmaceuticals market is segmented into Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to hold the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80–90% of diagnostic scans and around 30 million patient examinations every year.
“The endocrine tumors segment is projected to grow at the highest CAGR during the forecast period”
Based on application, the North American nuclear medicine market is categorized into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. The endocrine tumors segment is expected to be the fastest-growing application segment in the therapeutic nuclear medicine applications market. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.
“The US to witness the highest growth during the forecast period.”
The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to register the highest CAGR during the forecast period. The growth of the market in the US can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country
Break of primary participants was as mentioned below:
Research Coverage
This report studies the North American nuclear medicine market based on type, application, procedural volume, and country. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.
Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the North American nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the North American nuclear medicine and garner greater market shares.
The North American nuclear medicine market is projected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. The North American nuclear medicine market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide.
Growth in the market can primarily be attributed to factors such as increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.
“The Technetium-99m segment to hold the largest share of the SPECT radiopharmaceuticals market in 2019”
Based on type, the SPECT Radiopharmaceuticals market is segmented into Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to hold the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80–90% of diagnostic scans and around 30 million patient examinations every year.
“The endocrine tumors segment is projected to grow at the highest CAGR during the forecast period”
Based on application, the North American nuclear medicine market is categorized into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. The endocrine tumors segment is expected to be the fastest-growing application segment in the therapeutic nuclear medicine applications market. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.
“The US to witness the highest growth during the forecast period.”
The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to register the highest CAGR during the forecast period. The growth of the market in the US can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country
Break of primary participants was as mentioned below:
- By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
- By Designation: C-Level Executives: 35%, Directors: 25%, Others: 40%
- By Region: North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%
Research Coverage
This report studies the North American nuclear medicine market based on type, application, procedural volume, and country. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.
Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the North American nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the North American nuclear medicine and garner greater market shares.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH METHODOLOGY STEPS
2.2.1 SECONDARY DATA
2.2.1.1 Secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.3 KEY INSIGHTS FROM PRIMARY SOURCES
2.2.4 MARKET SIZE ESTIMATION METHODOLOGY
2.2.5 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.6 MARKET DATA ESTIMATION AND TRIANGULATION
2.2.7 ASSUMPTIONS OF THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NORTH AMERICAN NUCLEAR MEDICINE MARKET OVERVIEW
4.2 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE (2019)
4.3 NORTH AMERICAN DIAGNOSTIC PROCEDURES MARKET, BY TYPE (2019–2024)
4.4 NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET, BY TYPE (2019–2024)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence and prevalence of target conditions
5.2.1.2 Alpha radioimmunotherapy-based targeted cancer treatment
5.2.1.3 Initiatives to reduce the demand-supply gap of Mo-99
5.2.2 RESTRAINTS
5.2.2.1 Short half-life of radiopharmaceuticals
5.2.3 OPPORTUNITIES
5.2.3.1 Use of radiopharmaceuticals in neurological applications
6 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET: PIPELINE ASSESSMENT
6.1 INTRODUCTION
6.2 DIAGNOSTIC RADIOISOTOPES
6.3 THERAPEUTIC RADIOISOTOPES
7 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 DIAGNOSTIC NUCLEAR MEDICINE
7.2.1 SPECT RADIOPHARMACEUTICALS
7.2.1.1 TC-99M
7.2.1.1.1 TC-99M commanded the largest share of the North American SPECT radiopharmaceuticals market
7.2.1.2 I-123
7.2.1.2.1 I-123 to register the highest growth rate during the forecast period
7.2.1.3 Tl-201
7.2.1.3.1 Tl-201 is useful in the management of heart patients and aids in determining the requirement for bypass surgery
7.2.1.4 Ga-67
7.2.1.4.1 GA-67 is used in the diagnosis of lymphoma and hepatoma
7.2.1.5 Other SPECT isotopes
7.2.2 PET RADIOPHARMACEUTICALS
7.2.2.1 F-18
7.2.2.1.1 F-18 commanded the largest share of the North American PET radiopharmaceuticals market
7.2.2.2 Rb-82
7.2.2.2.1 Increasing number of PET procedures and high accuracy offered by the Rb-82 isotope to drive the growth of this market
7.2.2.3 Other PET isotopes
7.3 THERAPEUTIC NUCLEAR MEDICINE
7.3.1 ALPHA EMITTERS
7.3.1.1 Ra-223
7.3.1.1.1 Ra-223 to witness significant growth in the forecast period owing to its targeted properties over beta emitters
7.3.2 BETA EMITTERS
7.3.2.1 Iodine-131
7.3.2.1.1 Iodine-131 accounted for the largest share of the beta emitters market
7.3.2.2 Y-90
7.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel the growth of this segment
7.3.2.3 SM-153
7.3.2.3.1 Increasing incidence of bone metastasis to drive the growth of this segment
7.3.2.4 LU-177
7.3.2.4.1 Increasing incidence of neuroendocrine cancer is a key factor driving the growth of this segment
7.3.2.5 RH-186
7.3.2.5.1 RH-186 is commonly used for bone pain relief
7.3.2.6 Other beta emitters
7.3.3 BRACHYTHERAPY ISOTOPES
7.3.3.1 Iodine-125
7.3.3.1.1 I-125 accounted for the largest share of the North American brachytherapy isotopes market
7.3.3.2 Iridium-192
7.3.3.2.1 IR-192 is used to treat prostate cancer, skin cancer, sarcoids, and oral cancer
7.3.3.3 Palladium-103
7.3.3.3.1 PD-103 is best suited to treat aggressive tumors
7.3.3.4 Cesium-131
7.3.3.4.1 CS-131 is commonly used in gynecological applications
7.3.3.5 Other brachytherapy isotopes
8 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 SPECT APPLICATIONS
8.2.1.1 Cardiology
8.2.1.1.1 Rising incidence of CVD has increased the demand for cardiac diagnostic scans
8.2.1.2 Bone scans
8.2.1.2.1 Precision of SPECT in bone scanning has driven dependence on the technology
8.2.1.3 Pulmonary scans
8.2.1.3.1 SPECT/CT has shown high accuracy and sensitivity in pulmonary embolism applications
8.2.1.4 Thyroid applications
8.2.1.4.1 Introduction of dual SPECT/CT imaging is an important trend in the thyroid applications segment
8.2.1.5 Other SPECT applications
8.2.2 PET APPLICATIONS
8.2.2.1 Oncology
8.2.2.1.1 Increasing cancer incidence will fuel market growth
8.2.2.2 Cardiology
8.2.2.2.1 Growing preference for FDG in cardiac imaging is likely to boost market growth
8.2.2.3 Neurology
8.2.2.3.1 R&D on Alzheimer’s disease has positively affected the demand for nuclear medicine
8.2.2.4 Other PET applications
8.3 THERAPEUTIC APPLICATIONS
8.3.1 THYROID INDICATIONS
8.3.1.1 Increasing prevalence of thyroid disorders will fuel market growth
8.3.2 BONE METASTASIS
8.3.2.1 Introduction of novel therapies for bone metastasis will positively impact the market
8.3.3 ENDOCRINE TUMORS
8.3.3.1 The US dominates the therapeutic nuclear medicine market for endocrine tumor applications
8.3.4 LYMPHOMA
8.3.4.1 Development of new isotopes for the treatment of lymphoma presents huge growth opportunities
8.3.5 OTHER INDICATIONS
9 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT
9.1 INTRODUCTION
9.2 DIAGNOSTIC PROCEDURES
9.2.1 SPECT PROCEDURES
9.2.2 PET PROCEDURES
9.3 THERAPEUTIC PROCEDURES
9.3.1 BETA EMITTER PROCEDURES
9.3.2 ALPHA EMITTER PROCEDURES
9.3.3 BRACHYTHERAPY PROCEDURES
10 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY
10.1 INTRODUCTION
10.1.1 US
10.1.1.1 The US holds the largest share of the North American market
10.1.2 CANADA
10.1.2.1 Investments to secure medical isotope supply are likely to boost market growth
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET RANKING ANALYSIS
11.3 COMPETITIVE LEADERSHIP MAPPING
11.3.1 VISIONARY LEADERS
11.3.2 INNOVATORS
11.3.3 DYNAMIC DIFFERENTIATORS
11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO
11.4.1 PRODUCT LAUNCHES & APPROVALS
11.4.2 FUNDING
11.4.3 ACQUISITIONS
11.4.4 AGREEMENTS
11.4.5 PARTNERSHIPS
11.4.6 COLLABORATIONS
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 CARDINAL HEALTH
12.2 CURIUM
12.3 GE HEALTHCARE
12.4 LANTHEUS MEDICAL IMAGING, INC.
12.5 BAYER AG
12.6 BRACCO IMAGING S.P.A.
12.7 ECZACIBA?I-MONROL NUCLEAR PRODUCTS
12.8 NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
12.9 ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)
12.10 NTP RADIOISOTOPES SOC, LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
12.11 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)
12.12 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
12.13 ECKERT & ZIEGLER
12.14 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
12.15 PHARMALOGIC
12.16 INSTITUTE OF ISOTOPES CO., LTD.
12.17 SINOTAU PHARMACEUTICALS GROUP
12.18 ISOTOPIA MOLECULAR IMAGING LIMITED
12.19 SHINE MEDICAL TECHNOLOGIES
12.20 GLOBAL MEDICAL SOLUTIONS, LTD.
12.21 FDA-APPROVED RADIOPHARMACEUTICALS
12.22 RIGHT-TO-WIN
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
TABLE 3 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 4 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 5 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY 2017–2024 (USD MILLION)
TABLE 6 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN THE FACE OF SEVERE TC-99M SHORTAGES
TABLE 7 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 8 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 NORTH AMERICAN TC-99M MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 NORTH AMERICAN I-123 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 NORTH AMERICAN TI-201 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 NORTH AMERICAN GA-67 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 NORTH AMERICAN OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 14 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 15 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 NORTH AMERICAN F-18 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 NORTH AMERICAN RB-82 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 NORTH AMERICAN OTHER PET ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 20 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 NORTH AMERICAN RA-223 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 NORTH AMERICAN BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 23 NORTH AMERICAN BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 NORTH AMERICAN IODINE-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 NORTH AMERICAN Y-90 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 NORTH AMERICAN SM-153 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 NORTH AMERICAN LU-177 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 NORTH AMERICAN RE-186 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 29 NORTH AMERICAN OTHER BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 31 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 NORTH AMERICAN I-125 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICAN IRIDIUM-192 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICAN PALLADIUM-103 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICAN CESIUM-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICAN OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICAN DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICAN SPECT CARDIOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41 NORTH AMERICAN SPECT BONE SCANS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 NORTH AMERICAN SPECT PULMONARY SCANS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 43 NORTH AMERICAN SPECT THYROID APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 44 NORTH AMERICAN OTHER SPECT APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 46 NORTH AMERICAN PET ONCOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 NORTH AMERICAN PET CARDIOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 48 NORTH AMERICAN PET NEUROLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 49 NORTH AMERICAN OTHER PET APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 51 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 52 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR BONE METASTASIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 53 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMORS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR LYMPHOMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 55 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 57 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE PROCEDURES MARKET, BY TYPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 58 NORTH AMERICAN SPECT PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 59 NORTH AMERICAN PET PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 60 NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET, BY TYPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 61 NORTH AMERICAN BETA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 62 NORTH AMERICAN ALPHA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 63 NORTH AMERICAN BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 64 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 67 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 69 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 71 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 72 NORTH AMERICAN BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 74 NORTH AMERICAN THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 75 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 76 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 77 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 78 US: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 79 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 US: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 82 US: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 83 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 84 US: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 85 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 87 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 88 CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 89 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 CANADA: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 92 CANADA: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 CANADA: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 95 PRODUCT LAUNCHES & APPROVALS (2017–2019)
TABLE 96 FUNDING (2017–2019)
TABLE 97 ACQUISITIONS (2017–2019)
TABLE 98 AGREEMENTS (2017–2019)
TABLE 99 PARTNERSHIPS (2017–2019)
TABLE 100 COLLABORATIONS (2017–2019)
LIST OF FIGURES
FIGURE 1 RESEARCH METHODOLOGY: NORTH AMERICAN NUCLEAR MEDICINE MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING (1/2)
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING (2/2)
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 8 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 9 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 10 NORTH AMERICAN THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 11 HIGH PREVALENCE OF CANCER TO DRIVE THE MARKET DURING
THE FORECAST PERIOD
FIGURE 12 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN NUCLEAR MEDICINE MARKET
FIGURE 13 SPECT PROCEDURES TO ACCOUNT FOR THE LARGEST SHARE OF
THE MARKET IN 2024
FIGURE 14 ALPHA EMITTERS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET IN 2024
FIGURE 15 NORTH AMERICAN NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 16 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE, 2011–2025
FIGURE 17 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE, 2011–2025
FIGURE 18 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUB-TYPE, 2011–2025
FIGURE 19 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY APPLICATION, 2011–2025
FIGURE 20 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY PHASE, 2011–2025
FIGURE 21 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUB-TYPE, 2011–2025
FIGURE 22 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION, 2011–2025
FIGURE 23 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY PHASE, 2011–2025
FIGURE 24 NORTH AMERICAN NUCLEAR MEDICINE MARKET SNAPSHOT
FIGURE 25 KEY DEVELOPMENTS IN THE NORTH AMERICAN NUCLEAR MEDICINE MARKET, 2017–2019
FIGURE 26 NORTH AMERICAN NUCLEAR MEDICINE MARKET RANKING (2018)
FIGURE 27 NORTH AMERICAN NUCLEAR MEDICINE MARKET: COMPETITIVE
LEADERSHIP MAPPING (2018)
FIGURE 28 CARDINAL HEALTH: COMPANY SNAPSHOT (2018)
FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2018)
FIGURE 30 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 BAYER AG: COMPANY SNAPSHOT (2018)
FIGURE 32 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2018)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH METHODOLOGY STEPS
2.2.1 SECONDARY DATA
2.2.1.1 Secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.3 KEY INSIGHTS FROM PRIMARY SOURCES
2.2.4 MARKET SIZE ESTIMATION METHODOLOGY
2.2.5 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.6 MARKET DATA ESTIMATION AND TRIANGULATION
2.2.7 ASSUMPTIONS OF THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NORTH AMERICAN NUCLEAR MEDICINE MARKET OVERVIEW
4.2 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE (2019)
4.3 NORTH AMERICAN DIAGNOSTIC PROCEDURES MARKET, BY TYPE (2019–2024)
4.4 NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET, BY TYPE (2019–2024)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence and prevalence of target conditions
5.2.1.2 Alpha radioimmunotherapy-based targeted cancer treatment
5.2.1.3 Initiatives to reduce the demand-supply gap of Mo-99
5.2.2 RESTRAINTS
5.2.2.1 Short half-life of radiopharmaceuticals
5.2.3 OPPORTUNITIES
5.2.3.1 Use of radiopharmaceuticals in neurological applications
6 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET: PIPELINE ASSESSMENT
6.1 INTRODUCTION
6.2 DIAGNOSTIC RADIOISOTOPES
6.3 THERAPEUTIC RADIOISOTOPES
7 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 DIAGNOSTIC NUCLEAR MEDICINE
7.2.1 SPECT RADIOPHARMACEUTICALS
7.2.1.1 TC-99M
7.2.1.1.1 TC-99M commanded the largest share of the North American SPECT radiopharmaceuticals market
7.2.1.2 I-123
7.2.1.2.1 I-123 to register the highest growth rate during the forecast period
7.2.1.3 Tl-201
7.2.1.3.1 Tl-201 is useful in the management of heart patients and aids in determining the requirement for bypass surgery
7.2.1.4 Ga-67
7.2.1.4.1 GA-67 is used in the diagnosis of lymphoma and hepatoma
7.2.1.5 Other SPECT isotopes
7.2.2 PET RADIOPHARMACEUTICALS
7.2.2.1 F-18
7.2.2.1.1 F-18 commanded the largest share of the North American PET radiopharmaceuticals market
7.2.2.2 Rb-82
7.2.2.2.1 Increasing number of PET procedures and high accuracy offered by the Rb-82 isotope to drive the growth of this market
7.2.2.3 Other PET isotopes
7.3 THERAPEUTIC NUCLEAR MEDICINE
7.3.1 ALPHA EMITTERS
7.3.1.1 Ra-223
7.3.1.1.1 Ra-223 to witness significant growth in the forecast period owing to its targeted properties over beta emitters
7.3.2 BETA EMITTERS
7.3.2.1 Iodine-131
7.3.2.1.1 Iodine-131 accounted for the largest share of the beta emitters market
7.3.2.2 Y-90
7.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel the growth of this segment
7.3.2.3 SM-153
7.3.2.3.1 Increasing incidence of bone metastasis to drive the growth of this segment
7.3.2.4 LU-177
7.3.2.4.1 Increasing incidence of neuroendocrine cancer is a key factor driving the growth of this segment
7.3.2.5 RH-186
7.3.2.5.1 RH-186 is commonly used for bone pain relief
7.3.2.6 Other beta emitters
7.3.3 BRACHYTHERAPY ISOTOPES
7.3.3.1 Iodine-125
7.3.3.1.1 I-125 accounted for the largest share of the North American brachytherapy isotopes market
7.3.3.2 Iridium-192
7.3.3.2.1 IR-192 is used to treat prostate cancer, skin cancer, sarcoids, and oral cancer
7.3.3.3 Palladium-103
7.3.3.3.1 PD-103 is best suited to treat aggressive tumors
7.3.3.4 Cesium-131
7.3.3.4.1 CS-131 is commonly used in gynecological applications
7.3.3.5 Other brachytherapy isotopes
8 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 SPECT APPLICATIONS
8.2.1.1 Cardiology
8.2.1.1.1 Rising incidence of CVD has increased the demand for cardiac diagnostic scans
8.2.1.2 Bone scans
8.2.1.2.1 Precision of SPECT in bone scanning has driven dependence on the technology
8.2.1.3 Pulmonary scans
8.2.1.3.1 SPECT/CT has shown high accuracy and sensitivity in pulmonary embolism applications
8.2.1.4 Thyroid applications
8.2.1.4.1 Introduction of dual SPECT/CT imaging is an important trend in the thyroid applications segment
8.2.1.5 Other SPECT applications
8.2.2 PET APPLICATIONS
8.2.2.1 Oncology
8.2.2.1.1 Increasing cancer incidence will fuel market growth
8.2.2.2 Cardiology
8.2.2.2.1 Growing preference for FDG in cardiac imaging is likely to boost market growth
8.2.2.3 Neurology
8.2.2.3.1 R&D on Alzheimer’s disease has positively affected the demand for nuclear medicine
8.2.2.4 Other PET applications
8.3 THERAPEUTIC APPLICATIONS
8.3.1 THYROID INDICATIONS
8.3.1.1 Increasing prevalence of thyroid disorders will fuel market growth
8.3.2 BONE METASTASIS
8.3.2.1 Introduction of novel therapies for bone metastasis will positively impact the market
8.3.3 ENDOCRINE TUMORS
8.3.3.1 The US dominates the therapeutic nuclear medicine market for endocrine tumor applications
8.3.4 LYMPHOMA
8.3.4.1 Development of new isotopes for the treatment of lymphoma presents huge growth opportunities
8.3.5 OTHER INDICATIONS
9 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT
9.1 INTRODUCTION
9.2 DIAGNOSTIC PROCEDURES
9.2.1 SPECT PROCEDURES
9.2.2 PET PROCEDURES
9.3 THERAPEUTIC PROCEDURES
9.3.1 BETA EMITTER PROCEDURES
9.3.2 ALPHA EMITTER PROCEDURES
9.3.3 BRACHYTHERAPY PROCEDURES
10 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY
10.1 INTRODUCTION
10.1.1 US
10.1.1.1 The US holds the largest share of the North American market
10.1.2 CANADA
10.1.2.1 Investments to secure medical isotope supply are likely to boost market growth
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET RANKING ANALYSIS
11.3 COMPETITIVE LEADERSHIP MAPPING
11.3.1 VISIONARY LEADERS
11.3.2 INNOVATORS
11.3.3 DYNAMIC DIFFERENTIATORS
11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO
11.4.1 PRODUCT LAUNCHES & APPROVALS
11.4.2 FUNDING
11.4.3 ACQUISITIONS
11.4.4 AGREEMENTS
11.4.5 PARTNERSHIPS
11.4.6 COLLABORATIONS
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 CARDINAL HEALTH
12.2 CURIUM
12.3 GE HEALTHCARE
12.4 LANTHEUS MEDICAL IMAGING, INC.
12.5 BAYER AG
12.6 BRACCO IMAGING S.P.A.
12.7 ECZACIBA?I-MONROL NUCLEAR PRODUCTS
12.8 NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
12.9 ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)
12.10 NTP RADIOISOTOPES SOC, LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
12.11 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)
12.12 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
12.13 ECKERT & ZIEGLER
12.14 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
12.15 PHARMALOGIC
12.16 INSTITUTE OF ISOTOPES CO., LTD.
12.17 SINOTAU PHARMACEUTICALS GROUP
12.18 ISOTOPIA MOLECULAR IMAGING LIMITED
12.19 SHINE MEDICAL TECHNOLOGIES
12.20 GLOBAL MEDICAL SOLUTIONS, LTD.
12.21 FDA-APPROVED RADIOPHARMACEUTICALS
12.22 RIGHT-TO-WIN
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
TABLE 3 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 4 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 5 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY 2017–2024 (USD MILLION)
TABLE 6 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN THE FACE OF SEVERE TC-99M SHORTAGES
TABLE 7 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 8 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9 NORTH AMERICAN TC-99M MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 NORTH AMERICAN I-123 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 NORTH AMERICAN TI-201 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 NORTH AMERICAN GA-67 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13 NORTH AMERICAN OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 14 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 15 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 NORTH AMERICAN F-18 MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 NORTH AMERICAN RB-82 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 NORTH AMERICAN OTHER PET ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 20 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 NORTH AMERICAN RA-223 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 NORTH AMERICAN BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 23 NORTH AMERICAN BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24 NORTH AMERICAN IODINE-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 NORTH AMERICAN Y-90 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 NORTH AMERICAN SM-153 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 NORTH AMERICAN LU-177 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 NORTH AMERICAN RE-186 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 29 NORTH AMERICAN OTHER BETA EMITTERS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 31 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 NORTH AMERICAN I-125 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICAN IRIDIUM-192 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICAN PALLADIUM-103 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICAN CESIUM-131 MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 NORTH AMERICAN OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 38 NORTH AMERICAN DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICAN SPECT CARDIOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41 NORTH AMERICAN SPECT BONE SCANS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 NORTH AMERICAN SPECT PULMONARY SCANS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 43 NORTH AMERICAN SPECT THYROID APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 44 NORTH AMERICAN OTHER SPECT APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 46 NORTH AMERICAN PET ONCOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 NORTH AMERICAN PET CARDIOLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 48 NORTH AMERICAN PET NEUROLOGY APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 49 NORTH AMERICAN OTHER PET APPLICATIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 51 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 52 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR BONE METASTASIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 53 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMORS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR LYMPHOMA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 55 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 57 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE PROCEDURES MARKET, BY TYPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 58 NORTH AMERICAN SPECT PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 59 NORTH AMERICAN PET PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 60 NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET, BY TYPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 61 NORTH AMERICAN BETA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 62 NORTH AMERICAN ALPHA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 63 NORTH AMERICAN BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2024 (THOUSAND PROCEDURES)
TABLE 64 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 67 NORTH AMERICAN SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 69 NORTH AMERICAN PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 71 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 72 NORTH AMERICAN BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 NORTH AMERICAN BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 74 NORTH AMERICAN THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 75 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 76 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 77 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 78 US: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 79 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 US: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 82 US: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 83 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 84 US: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 85 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 87 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 88 CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 89 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 CANADA: PET APPLICATIONS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 92 CANADA: BETA EMITTERS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 94 CANADA: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 95 PRODUCT LAUNCHES & APPROVALS (2017–2019)
TABLE 96 FUNDING (2017–2019)
TABLE 97 ACQUISITIONS (2017–2019)
TABLE 98 AGREEMENTS (2017–2019)
TABLE 99 PARTNERSHIPS (2017–2019)
TABLE 100 COLLABORATIONS (2017–2019)
LIST OF FIGURES
FIGURE 1 RESEARCH METHODOLOGY: NORTH AMERICAN NUCLEAR MEDICINE MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING (1/2)
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING (2/2)
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 NORTH AMERICAN NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 8 NORTH AMERICAN SPECT APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 9 NORTH AMERICAN PET APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 10 NORTH AMERICAN THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 11 HIGH PREVALENCE OF CANCER TO DRIVE THE MARKET DURING
THE FORECAST PERIOD
FIGURE 12 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN NUCLEAR MEDICINE MARKET
FIGURE 13 SPECT PROCEDURES TO ACCOUNT FOR THE LARGEST SHARE OF
THE MARKET IN 2024
FIGURE 14 ALPHA EMITTERS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN THERAPEUTIC PROCEDURES MARKET IN 2024
FIGURE 15 NORTH AMERICAN NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 16 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE, 2011–2025
FIGURE 17 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE, 2011–2025
FIGURE 18 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUB-TYPE, 2011–2025
FIGURE 19 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY APPLICATION, 2011–2025
FIGURE 20 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY PHASE, 2011–2025
FIGURE 21 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUB-TYPE, 2011–2025
FIGURE 22 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION, 2011–2025
FIGURE 23 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY PHASE, 2011–2025
FIGURE 24 NORTH AMERICAN NUCLEAR MEDICINE MARKET SNAPSHOT
FIGURE 25 KEY DEVELOPMENTS IN THE NORTH AMERICAN NUCLEAR MEDICINE MARKET, 2017–2019
FIGURE 26 NORTH AMERICAN NUCLEAR MEDICINE MARKET RANKING (2018)
FIGURE 27 NORTH AMERICAN NUCLEAR MEDICINE MARKET: COMPETITIVE
LEADERSHIP MAPPING (2018)
FIGURE 28 CARDINAL HEALTH: COMPANY SNAPSHOT (2018)
FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2018)
FIGURE 30 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 BAYER AG: COMPANY SNAPSHOT (2018)
FIGURE 32 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2018)
